Variables | Original Cohort (n = 165) | Independent Cohort (n = 107) | P |
---|---|---|---|
Age - yr (mean) | 65.2 ± 12.0 | 64.1 ± 13.3 | 0.51* |
Gender - no. of patients (%) | Â | Â | 0.93+ |
   Male | 135 (81.8) | 88 (82.2) |  |
   Female | 30 (18.2) | 19 (17.8) |  |
Grade - no. of patients (%) | Â | Â | 0.76+ |
   Low | 105 (63.6) | 70 (65.4) |  |
   High | 60 (36.4) | 37 (34.6) |  |
Stage - no. of patients (%) | Â | Â | 0.14+ |
   NMIBC | 103 (62.4) | 76 (71.0) |  |
Ta |    23 (22.3) |    21 (27.6) |  |
T1 |    80 (77.7) |    55 (72.4) |  |
   MIBC | 62 (37.6) | 31 (29.0) |  |
T2N0M0 |    26 (41.9) |    8 (25.8) |  |
T3 N0M0 |    13 (21.0) |    8 (25.8) |  |
T4/Any T N+/M+ |    23 (37.1) |    15 (48.4) |  |
Recurrence - no. of patients with NMIBC (%) | Â | Â | 0.94+ |
   No | 67 (65.0) | 49 (64.5) |  |
   Yes | 36 (35.0) | 27 (35.5) |  |
Progression - no. of patients (%) | Â | Â | Â |
   NMIBC |  |  | 0.97+ |
No | 92 (89.3) | 68 (89.5) | Â |
Yes | 11 (10.7) | 8 (10.5) | Â |
   MIBC |  |  | 1.00+ |
No | 42 (67.7) | 21 (67.7) | Â |
Yes | 20 (32.3) | 10 (32.3) | Â |
Survival - no. of patients with MIBC (%) | Â | Â | Â |
   Cancer-specific |  |  | 0.18+ |
Alive | 33 (53.2) | 21 (67.7) | Â |
Deceased | 29 (46.8) | 10 (32.3) | Â |
   Overall survival |  |  | 0.37+ |
Alive | 28 (45.2) | 11 (35.5) | Â |
Deceased | 34 (54.8) | 20 (64.5) | Â |
Mean follow-up - months | 48.4 | 42.5 | 0.25* |